Muscletech SX-7 Black Onyx Shatter
Natural health product licensed in Canada
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Choline Source : Bitartrate de choline | 75 mg | Not calculated |
| Choline Source : Alfoscérate de choline | 75 mg | Not calculated |
| Adénosine 5'-(disodium triphosphate) Source : Adénosine triphosphate disodium Potency : 368 mg Adenosine triphosphate | 400 mg | Not calculated |
| Acide 2-aminoéthanesulfonique Source : Taurine | 1 g | Not calculated |
| L-Citrulline Source : Malate de citrulline | 3 g | Not calculated |
| 7,9-Dihydro-1,3,7,9-tétraméthyl-1H-purine-2,6,8(3H)-trione Source : Théacrine | 40 mg | Not calculated |
Non-medicinal ingredients
Saveur, Dioxyde de silicium, Acide DL-malique, Acide citrique, Sucralose, Acésulfame potassium, Maltodextrine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Portion(s) | 1 Tous les jours |
Uses authorised in Canada
Helps (temporarily) to promote alertness and wakefulness, and to enhance cognitive performance. Helps (temporarily) to relieve fatigue, to promote endurance, and to enhance motor performance. Helps to delay muscle fatigue by increasing carnosine levels. Helps to temporarily increase thermogenesis and basal metabolic rate.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
May cause a flushing, tingling and/or prickling sensation of the skin, in which case, reduce the dose. Caffeine has been shown to reduce blood flow to the heart muscle during exercise which might lead to cardiovascular complications such as chest pain, and irregular heartbeat even in healthy individuals. If those symptoms occur discontinue use and consult a health care practitioner. Hypersensitivity/allergy is known to occur, in which case, discontinue use. Anxiety, tachycardia (rapid heart rate), palpitations, insomnia, restlessness, nervousness, tremor and headache may occur; in which case discontinue use and consult a health care practitioner.
- Précautions et mises en garde
Consult a health care practitioner prior to use if you are taking cardiac glycosides such as digitalis/digoxin, or blood pressure medication. Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Ensure to drink enough fluid before, during and after exercise. Consult a health care practitioner prior to use if you are taking lithium. Do not use if you have cardiovascular disease risk factors (e.g. high blood pressure, high cholesterol and/or triglycerides, obesity) or glaucoma. Consult a health care practitioner prior to use if you have destrusor instability (overactive bladder syndrome). Consumption with natural health products (e.g. bitter orange extract, synephrine, octopamine, ephedra) or other drugs (e.g. ephedrine) which increase blood pressure is not recommended. Consumption with other caffeine-containing products (e.g. medications, coffee, tea, colas, cocoa, guarana, maté) is not recommended. This product is not intended as a substitute for sleep.
Product record
- Licence holder
- Iovate Health Sciences International Inc.
- NPN or DIN-HM
- 80091027
- Status
- Active licence
- Licence date
- 28 February 2019
- Revision date
- Not provided
- Form
- Poudre
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80091027
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Muscletech SX-7 Black Onyx Shatter”, https://compoatlas.com/en/supplements/canada/80091027-muscletech-sx-7-black-onyx-shatter, updated 28 February 2019.